Acute Coronary Syndrome
Conditions
Keywords
Acute Coronary Syndrome, Acute Myocardial Infarction, coronary heart disease, prognosis
Brief summary
The MPCS-ACS Study (Multicenter Prospective Cohort Study on Acute Coronary Syndrome) is a comprehensive, forward-looking research project designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) who declined coronary artery bypass grafting (CABG) and underwent percutaneous coronary intervention (PCI) instead. Leveraging a multicenter approach, the study aims to collect data from a diverse patient population, thereby enhancing the generalizability and clinical relevance of its findings. Upon enrollment, detailed information is gathered, including demographic data, clinical history, and key biochemical markers. The study also documents the various medication regimens prescribed during hospitalization to assess their influence on patient outcomes. A key feature of MPCS-ACS is its rigorous follow-up protocol, which involves regularly monitoring patients after discharge to track recovery progress and the occurrence of any subsequent cardiovascular events. This methodical approach is designed to generate valuable insights into the long-term prognosis of ACS patients treated with PCI, ultimately contributing to the refinement of therapeutic strategies and improving the standard of care across all participating centers.
Detailed description
The Multicenter Acute Coronary Syndrome Prognosis Cohort Study (MPCS-ACS) is a comprehensive, longitudinal research initiative designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) across diverse healthcare settings. Conducted in collaboration with multiple hospitals, this study aims to collect and analyze data from ACS patients admitted between June 1, 2016, and May 31, 2021. The study will gather an extensive range of variables, including therapeutic interventions, biochemical markers relevant to ACS management, as well as key demographic and clinical history data. By analyzing these factors, the study seeks to gain a deeper understanding of ACS treatment practices during the study period and assess their clinical efficacy. A robust follow-up protocol is a cornerstone of MPCS-ACS, featuring routine evaluations conducted every six to twelve months after patient discharge. Follow-ups will incorporate both in-person visits and telecommunication to accommodate participants unable to return to the hospital. This dual approach is designed to maximize participant retention and ensure high-quality data collection, thereby enhancing the study's validity and impact. Through its rigorous methodology and collaborative framework, the MPCS-ACS aims to identify key prognostic factors and outcomes for ACS patients. The ultimate goal is to inform the optimization of care strategies and elevate the standards of cardiovascular treatment across diverse healthcare systems.
Interventions
OTHERNo Intervention - Observational Only
Clinical Follow-Up
Sponsors
Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University
The Third Affiliated Hospital of Jinzhou Medical University
Xiang Xie
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. Men and women aged between 18 and 79 years. 2. Patients diagnosed with Acute Coronary Syndrome (ACS), including Unstable Angina (UA) and Acute Myocardial Infarction (AMI), based on typical clinical symptoms, changes in electrocardiographic (ECG) readings, and elevated cardiac biomarkers. 3. Patients who underwent coronary angiography confirming coronary artery stenosis and opted for PCI treatment instead of coronary artery bypass grafting (CABG). 4. Patients who are under long-term follow-up.
Exclusion criteria
1. Patients with rheumatic heart disease, valvular heart disease, or congenital heart disease. 2. Patients with malignant tumors or hematologic diseases. 3. Patients with severe liver or kidney dysfunction or pulmonary heart disease. 4. Patients with a life expectancy of less than one year due to terminal illnesses such as advanced cancer or chronic kidney disease requiring dialysis. 5. Patients whose health is severely impacted by acute infections.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death | 10 years | All-cause mortality, Cardiac mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiovascular and cerebrovascular events (MACCE） | 10 years | cardiac death, non-fatal myocardial infarction, aortic events such as aortic dissection and aortic aneurysm rupture, episodes of unstable angina requiring medical intervention, hospitalization for acute heart failure assessed at Killip Class IV, target vessel revascularization, cerebrovascular events encompassing ischemic stroke, hemorrhagic stroke, transient ischemic attacks (TIAs) and subarachnoid hemorrhage. |
| revascularization of the target vesse | 10 years | Revascularization of the target vessel was performed using percutaneous coronary intervention (PCI). |
| episodes of unstable angina necessitating medical intervention | 10 years | Episodes of unstable angina requiring medical intervention were managed with urgent therapeutic measures. |
| Major adverse cardiovascular events (MACE) | 10 years | cardiac death, non-fatal myocardial infarction, significant aortic pathologies including aortic dissection and rupture of aortic aneurysms, episodes of unstable angina necessitating medical intervention, hospitalization for acute heart failure classified as Killip Class IV, and revascularization of the target vessel. |
| non-fatal myocardial infarction | 10 years | non-fatal myocardial infarction |
| cerebrovascular events | 10 years | ischemic stroke, hemorrhagic stroke, transient ischemic attacks (TIAs) and subarachnoid hemorrhage. |
| hospitalization for acute heart failure classified as Killip Class IV | 10 years | hospitalization for acute heart failure classified as Killip Class IV |
Countries
China
Outcome results
None listed